19 stories mentioning PHVSUpdated 1h ago
Every FINWIRES story that references PHVS, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Johannes Gerardus Christiaan Petrus Schikan, Director, on September 17, 2026, sold 200,000 shares in Pharvaris (PHVS) for $7,000,000. Following the Form 4 filing with the SEC, Schikan has control over a total of 115,167 common shares of the company, with 115,167 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526396689/xslF345X05/ownership.xml
Stefan Andreas Abele, Chief Technical Operations Officer, on September 15, 2026, sold 46,400 shares in Pharvaris (PHVS) for $1,771,125. Following the Form 4 filing with the SEC, Abele has control over a total of 39,068 common shares of the company, with 39,068 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526394103/xslF345X05/ownership.xmlPrice: $37.87, Change: $+0.32, Percent Change: +0.85%
Robert Glassman, Director, on September 15, 2026, sold 8,667 shares in Pharvaris N.v. (PHVS) for $331,716. Following the Form 4 filing with the SEC, Glassman has control over a total of 10,500 common shares of the company, with 10,500 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526393860/xslF345X05/ownership.xml
Wim Souverijns, Chief Commercial Officer, on September 14, 2026, sold 26,090 shares in Pharvaris (PHVS) for $1,023,575. Following the Form 4 filing with the SEC, Souverijns has control over a total of 39,021 common shares of the company, with 39,021 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526392895/xslF345X05/ownership.xmlPrice: $37.69, Change: $-0.37, Percent Change: -0.97%
BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema treatment space, and its shares are expected to settle within an in-line trading range in the near term, RBC Capital Markets said in a Thursday note.Pharvaris' (PHVS) released stronger-than-expected data for deucrictibant XR, its competing oral agent for treating hereditary angioedema, and conversations with key opinion leaders revealed that more doctors may move patients from Ordaleyo to the rival offering than consensus numbers would imply, RBC analysts said.The analysts said they see Ordaleyo likely continuing to grow in the near term, but now project Ordaleyo's long-term annual revenue to drop to a range of $400 million to $450 million from their previous estimate of $500 million to $550 million.Meanwhile, the analysts said they are optimistic that BioCryst's long-acting injectable navenibart will drive a new phase of growth, clinical data is likely still a year away, and the launch of deucrictibant XR could limit how much the company's stock rises, even with quarterly beats.RBC downgraded the company's stock rating to sector-perform from outperform and reduced the price target to $11 from $13.Price: $8.11, Change: $-0.70, Percent Change: -7.95%
Peng Lu, President, on September 08, 2026, sold 15,000 shares in Pharvaris (PHVS) for $610,134. Following the Form 4 filing with the SEC, Lu has control over a total of 65,179 common shares of the company, with 65,179 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526386096/xslF345X05/ownership.xmlPrice: $37.57, Change: $-0.28, Percent Change: -0.73%
Pharvaris (PHVS) could gain greater market share in hereditary angioedema with its deucrictibant extended-release or XR tablets following compelling phase 3 data, RBC Capital Markets said in a Wednesday note.The brokerage said the global phase 3 study's 83% placebo-adjusted reduction in the mean monthly attack rate, along with robust responder data, suggests deucrictibant XR could be a front-line option in HAE as its efficacy rivals that of injectable therapies.Safety data was generally clean and the product candidate was well tolerated, but RBC flagged liver enzyme elevations that will warrant monitoring as data from the ongoing open-label extension study matures.The investment firm raised its global peak sales estimate for deucrictibant XR to about 720 million euros ($838 million) from 670 million euros previously, citing greater market-share potential among prophylaxis-naive patients and those using oral or injectable alternatives.RBC raised its price target on Pharvaris to $62 from $52, with an outperform rating.Price: $37.38, Change: $-0.47, Percent Change: -1.23%
Roivant Sciences (ROIV) shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, met its primary and secondary endpoints.More than 13.5 million shares of the company traded intraday compared with a daily average of about 6.26 million.Intel (INTC) is expected to raise personal computer central processing unit prices by another 10% in early October, Digitimes reported, citing supply chain sources.Shares jumped 10%, with intraday trading volume at over 86.0 million, versus the stock's daily average of about 113.4 million.Pharvaris (PHVS) said that a global phase 3 study of deucrictibant extended-release tablets met the primary endpoint of reducing the mean monthly attack rate by 83%, compared with placebo, in people with hereditary angioedema.Wedbush Securities adjusted Pharvaris' price target to $50 from $42 while maintaining its outperform rating.Shares climbed 10% as intraday trading volume catapulted to over 4.20 million from a daily average of about 510,000.Price: $42.08, Change: $+7.15, Percent Change: +20.47%
Pharvaris (PHVS) has an average rating of buy and mean price target of $48.32, according to analysts polled by FactSet.Price: $38.52, Change: $+3.27, Percent Change: +9.28%
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Tuesday's premarket activity amid rising oil prices.US stock futures were also mixed, with S&P 500 Index futures down 0.2%, Dow Jones Industrial Average futures slipping 0.8%, and Nasdaq futures advancing 0.1% before the start of regular trading.The National Federation of Independent Business' monthly Small Business Optimism Index fell to a reading of 98.7 in August from 99.8 in July and was below a 100.8 reading a year ago.The New York Fed's inflation expectations report for August will be released at 11 am ET.The July consumer credit data is slated for a 3 pm ET release.In premarket activity, bitcoin was down by 1.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.1% lower, Ether ETF (EETH) advanced 0.4%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated 1.1%, the Vanguard Health Care Index Fund (VHT) was down 0.8%, while the iShares US Healthcare ETF (IYH) slipped 0.5%. The iShares Biotechnology ETF (IBB) was 1% lower.Pharvaris (PHVS) stock was up more than 16% premarket after the company said that a global phase 3 study of deucrictibant extended-release tablets met the primary endpoint of reducing the mean monthly attack rate by 83%, compared with placebo, in people with hereditary angioedema.Winners and Losers:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.2%, while the Vanguard Industrials Index Fund (VIS) and the iShares US Industrials ETF (IYJ) were inactive.Bloom Energy (BE) was up 6% premarket, after a 7.4% increase in Friday's session. The company will join the S&P 500, effective Sept. 21, S&P Dow Jones Indices said Friday.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 0.6%, the iShares US Technology ETF (IYW) and the iShares Expanded Tech Sector ETF (IGM) were inactive. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was inactive, while the iShares Semiconductor ETF (SOXX) rose by 1.7%.IonQ (IONQ) shares were up 6% after the company raised its 2026 revenue outlook to a range of $450 million to $460 million, up from $280 million to $290 million anticipated previously, reflecting contributions from SkyWater Technology following its acquisition on July 31.EnergyThe iShares US Energy ETF (IYE) was inactive, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 1%.Solaris Energy Infrastructure (SEI) stock was 6% higher after the company raised its guidance for Q3 and Q4 adjusted earnings before interest, taxes, depreciation and amortization.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.3%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) and the iShares US Consumer Staples ETF (IYK) were inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.7%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.General Mills (GIS) shares were up more than 1% pre-bell after the company reaffirmed its fiscal 2027 financial guidance.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated 0.7%. Direxion Daily Financial Bull 3X Shares (FAS) was down 2.1%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 2.1% higher.First Citizens BancShares (FCNCA) shares were up 1% in early-hours activity after the company said it converted 138 bank branches that it acquired from Bank of Montreal (BMO).CommoditiesFront-month US West Texas Intermediate crude oil was up by 2.1% at $93.43 per barrel on the New York Mercantile Exchange. Natural gas was 0.5% lower at $2.96 per 1 million British Thermal Units. The United States Oil Fund (USO) rose 2%, while the United States Natural Gas Fund (UNG) advanced 0.6%.Gold futures for November were down by 0.7% at $4,446.90 an ounce on the Comex. Silver futures advanced 0.2% to $66.85 an ounce. SPDR Gold Shares (GLD) decreased 0.8%, and the iShares Silver Trust (SLV) was flat.
Pharvaris (PHVS) said Tuesday that a global phase 3 study of deucrictibant extended-release tablets met the primary endpoint of reducing the mean monthly attack rate by 83%, compared with placebo, in people with hereditary angioedema.The primary endpoint and all secondary efficacy endpoints met statistical significance, the company said.Among participants with HAE Type 1 or Type 2, the mean monthly attack rate was 87% lower with deucrictibant XR versus placebo, while protection began within the first week and was sustained through the 24 weeks of study treatment, the company said.Deucrictibant XR was well tolerated, with most treatment-emergent adverse events mild or moderate and no treatment-related serious adverse events reported.Pharvaris plans to submit a new drug application to the US Food and Drug Administration for prophylaxis of bradykinin-mediated angioedema attacks in H1 2027.Shares of the company were over 24% higher in premarket activity Tuesday.Price: $44.04, Change: $+8.79, Percent Change: +24.94%
Pharvaris (PHVS) remains well-positioned ahead of results from its phase 3 CHAPTER-3 trial of deucrictibant XR, with positive data potentially driving significant upside, RBC Capital Markets said in a note Wednesday.The analysts said they continue to see a favorable risk/reward setup ahead of the results. They project that results showing at least a 70% reduction in attack rates with clean tolerability could drive about 50% upside, while downside appears more limited at around 30%.The near-term opportunity in acute hereditary angioedema, or HAE, also remains on track, with a PDUFA date of April 23, 2027, they added."The key question that we have been receiving from investors into the CHAPTER-3 readout has been what Pharvaris would need to demonstrate in order to be commercially competitive," the analysts said.If the trial shows a 77% to 80% reduction in HAE attacks, it could put deucrictibant on par with leading injectable treatments. Strong results could also support significant patient adoption, the analysts added.RBC raised its price target to $52 from $51 and kept its outperform rating on Pharvaris.Price: $34.46, Change: $-2.01, Percent Change: -5.50%
Peng Lu, Chief Medical Officer, on June 25, 2026, sold 29,700 shares in Pharvaris (PHVS) for $1,018,832. Following the Form 4 filing with the SEC, Lu has control over a total of 65,631 common shares of the company, with 65,631 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526288838/xslF345X05/ownership.xml
Elisabeth Bjork, Director, on May 20, 2026, sold 10,000 shares in Pharvaris (PHVS) for $293,166. Following the Form 4 filing with the SEC, Bjork has control over a total of 15,167 common shares of the company, with 15,167 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526236432/xslF345X05/ownership.xmlPrice: $29.99, Change: $-0.55, Percent Change: -1.80%
Peng Lu, Chief Medical Officer, on May 01, 2026, sold 14,166 shares in Pharvaris (PHVS) for $427,419. Following the Form 4 filing with the SEC, Lu has control over a total of 66,083 common shares of the company, with 66,083 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526206273/xslF345X05/ownership.xmlPrice: $29.94, Change: $-0.08, Percent Change: -0.27%
Anne Lesage, Chief Early Development, on April 29, 2026, sold 48,300 shares in Pharvaris N.v. (PHVS) for $1,459,970. Following the Form 4 filing with the SEC, Lesage has control over a total of 190,419 common shares of the company, with 56,450 shares held directly and 133,969 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526201925/xslF345X05/ownership.xml
Johannes Gerardus Christiaan Petrus Schikan, Director, on April 29, 2026, sold 32,900 shares in Pharvaris N.v. (PHVS) for $996,545. Following the Form 4 filing with the SEC, Schikan has control over a total of 355,167 common shares of the company, with 355,167 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526201931/xslF345X05/ownership.xml
Anne Lesage, Chief Early Development Officer, on April 22, 2026, sold 14,700 shares in Pharvaris (PHVS) for $441,726. Following the Form 4 filing with the SEC, Lesage has control over a total of 213,319 common shares of the company, with 56,450 shares held directly and 156,869 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526176222/xslF345X05/ownership.xmlPrice: $28.49, Change: $+1.20, Percent Change: +4.40%
Berndt Modig, Director, Chief Executive Officer, on April 09, 2026, sold 23,333 shares in Pharvaris (PHVS) for $647,281. Following the Form 4 filing with the SEC, Modig has control over a total of 1,092,084 common shares of the company, with 142,084 shares held directly and 950,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526150954/xslF345X05/ownership.xmlPrice: $26.52, Change: $-0.55, Percent Change: -2.03%
